To listen to some of the predictions about the future of the cannabis industry, you would think financial analysts had been partaking heavily of the product.
The European cannabis market will be worth €123bn (£106bn) by 2028, according to London-based analysis firm Prohibition Partners. That is more than twice the revenues that Apple reported in the region last year and larger than the annual economic output of Ukraine.
Some of the more fanciful forecasts suggest that the world is witnessing the birth of an industry that could be worth from $500bn to $1tn.
Sativa Investments (NEX:SATI) is the UK’s first medicinal cannabis investment vehicle. After investing in two North American businesses, it is now progressing a UK seed to consumer investment strategy with 100% ownership of businesses involved in the production, testing and compliance, research & development including pharmacology, commercialisation and sales & marketing of medicinal cannabis and cannabidiol products. Two UK businesses, George Botanicals and PhytoVista Laboratories, are already fully operational.